Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
157.10B
Market cap157.10B
Price-Earnings ratio
19.93
Price-Earnings ratio19.93
Dividend yield
6.35%
Dividend yield6.35%
Average volume
36.98M
Average volume36.98M
High today
$27.67
High today$27.67
Low today
$27.00
Low today$27.00
Open price
$27.18
Open price$27.18
Volume
37.97M
Volume37.97M
52 Week high
$27.94
52 Week high$27.94
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 157.1B, Pfizer(PFE) trades at $27.58. The stock has a price-to-earnings ratio of 19.93 and currently yields dividends of 6.3%.

During the trading session on 2026-02-27, Pfizer(PFE) shares reached a daily high of $27.67 and a low of $27.00. At a current price of $27.58, the stock is +2.1% higher than the low and still -0.3% under the high.

Trading volume for Pfizer(PFE) stock has reached 37.97M, versus its average volume of 36.98M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.

PFE News

TipRanks 4h
Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 1 study called “A PHASE 1, OPEN-LABEL, RANDOMIZED, S...

TipRanks 4h
Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is launching a phase 2 study called “A PHASE 2, RANDOMIZED, DOUBLE-BLIN...

TipRanks 4h
Pfizer’s Tranquillo Vitiligo Trial Nears Key Data Phase, Setting Up a New Dermatology Catalyst for PFE

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a late-stage study called Tranquillo to test an oral drug fo...

Analyst ratings

59%

of 29 ratings
Buy
31%
Hold
58.6%
Sell
10.3%

More PFE News

TipRanks 6h
Pfizer, Astellas announce results from Phase 3 EV-304 trial for PADCEV

Pfizer (PFE) and Astellas Pharma (ALPMY) announced positive results from the Phase 3 EV-304 clinical trial for PADCEV, a Nectin-4 directed antibody-drug conjuga...

Simply Wall St 22h
Pfizer Targets Obesity And Oncology To Rebuild Post COVID 19 Growth

Pfizer secured exclusive commercialization rights to Sciwind's ecnoglutide in China for type 2 diabetes and potential obesity treatment. The company expanded i...

Pfizer Targets Obesity And Oncology To Rebuild Post COVID 19 Growth
Benzinga 2d
Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment

Pfizer Inc. (NYSE:PFE) shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the BRAFTOVI combination regime...

Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment
TipRanks 2d
Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study: What Investors Should Watch

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has ended a Phase 1b trial titled “A Phase 1b, Two-Part, Randomized, Do...

TipRanks 2d
Pfizer’s Pneumococcal Vaccine Study in China: What the Latest Trial Update Means for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 1 study in China called “A Phase 1, Randomized, Doub...

TipRanks 2d
Novavax price target raised to $8 from $7 at TD Cowen

TD Cowen raised the firm’s price target on Novavax (NVAX) to $8 from $7 and keeps a Hold rating on the shares. The firm previewed its Q4 results and updated est...

TipRanks 3d
RBC starts Pfizer at Underperform on ‘insurmountable’ patent cliff

As previously reported, RBC Capital initiated coverage of Pfizer (PFE) with an Underperform rating and $25 price target reflecting an “insurmountable” $15B-$20B...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.